During in vitro fertilization, 22 human embryos were exposed to hepatitis B virus (HBV) in contaminated human serum present in the culture medium. All mothers experienced hepatitis B during the first trimester of pregnancy, and two had hepatitis B surface antigen and HBV DNA, as determined by PCR, at the time of delivery. No HBV DNA was found in serum or lymphocytes from the exposed 22 infants. HBV DNA was also absent from one infant at autopsy.
During an in vitro fertilization (IVF) program, 128 women were exposed to hepatitis B virus (HBV) (14) . Seventy-nine women became clinically infected (9) . Because of a lack of communication between the outpatient clinic of the Department of Obstetrics and the IVF laboratory, the results of hepatitis B surface antigen (HBsAg) tests was delayed in reaching the IVF laboratory, and an HBV-positive serum sample apparently was used to prepare a pool of serum. This pool of serum was added to the embryo culture medium and was used during a 6-week period. Clinical cases of hepatitis B occurred at 3 months after the use of this particular batch of culture medium. All HBsAg, HBeAg, and anti-HBc were determined by radioimmunoassays (Abbott Laboratories, North Chicago, Ill.).
DNAs from serum samples (300 ,ul) and lymphocytes were isolated as described before (9) . From an infant who died 12 days after birth, DNA was isolated from frozen tissues, i.e., lung, heart, liver, brain, stomach, spleen, adrenal gland, and large and small intestine, as described previously (10) . The PCR was performed, and the amplified DNA was analyzed exactly as described previously (9) .
Oligonucleotide primers and probes specific for the HBV surface and hepatitis B core genes were selected and synthesized on a 380A DNA synthesizer (Applied Biosystems) (4, 8) .
As a positive control for every PCR assay, 3-globin-specific primers were used to check the quality of the template DNA (11) . All specimens showed f3-globin-specific amplification products, warranting a reliable interpretation of the PCR results. In every experiment, water and human placental DNA were included as negative controls.
Infants (group I) born from women infected because of IVF showed perinatal anti-HBc in their serum. Over a period of 6 to 12 months, this anti-HBc became undetectable in all infants, a result which makes a subclinical infection unlikely. HBsAg was never detected after birth (14) .
Passive transfer of anti-HBs was observed in 16 of the 22 children. The six anti-HBs-negative children were born from three anti-HBs-negative mothers; two women were HBsAg positive at delivery, and one had just resolved HBsAg. All cord blood samples (n = 22) and maternal serum samples (n = 18) were HBV DNA negative, with the exception of 2 maternal serum samples from HBsAg-and HBeAgpositive mothers at delivery. One of these two women became a chronic carrier, and the other underwent late HBsAg seroconversion. Their One infant in a set of triplets (group I) delivered by a woman who was HBsAg and HBeAg positive at delivery died 12 days postpartum from septic candidiasis. Autopsy material from frozen tissues of the lung, heart, liver, brain, stomach, spleen, adrenal gland, and large and small intestine was investigated for HBV DNA by PCR and found to be negative.
In this study, HBV DNA could not be demonstrated by PCR in any of the children of mothers exposed to HBV during IVF. The children could have had contact with HBV on three occasions. First, all 22 children born from infected (n = 18) women may have been in contact with HBV during embryo cultivation. Second, 18 women were HBsAg positive during pregnancy (3 women even until the third trimester), a fact that may have resulted in in utero infection (22 children). Third, two women were still HBsAg and HBeAg positive at delivery and may have infected their children perinatally (during birth or later) (four children).
Exposure of oocytes to HBV may occur as a result of sexual intercourse with an HBV-infected partner or donor insemination (2). It is not known whether such events lead to in utero infection of the embryo. HBV infection during the third trimester has been reported to pose a 70% risk of transfer to the infant (12, 13) . HBV infection of children of (chronic) HBsAg-and HBeAg-positive mothers is manifested in about 90% of cases (1) . In our study, the four children of HBsAgpositive mothers were given prophylactic hepatitis B immunoglobulin and hepatitis B vaccine. Lack of replication or latency of HBV in these children is presumed on the basis of the absence of HBsAg after birth, the ultimate disappearance of anti-HBc, and the absence of HBV DNA in serum at birth and in lymphocytes during the first year of life. Determination of HBV DNA in lymphocytes was the only option as a noninvasive method for the detection of possible integrated HBV DNA sequences. In our study, however, no integration events could be recognized with primer sets specific for different parts of the viral genome. Moreover, in one case, cells from various organs could also be analyzed for HBV DNA. HBV-DNA was not detected in any of the tissues sampled.
Since none of the children had any signs of viral infection, one can speculate that cells in early embryonic phases may lack receptors for HBV or a metabolic system for viral multiplication.
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